Omega-3 (EPA/DHA) Benefits & Safety

Q: Did the REDUCE-IT trial's benefit come from a bad placebo, not the fish oil?

This is a genuine, unresolved scientific controversy, not a fringe theory. REDUCE-IT used mineral oil as its placebo, and a later biomarker sub-study found the mineral-oil group had significant increases in LDL cholesterol, oxidized LDL, C-reactive protein, interleukin-6, interleukin-1-beta, lipoprotein(a), and homocysteine over the trial. Critics, including the senior investigator of the rival STRENGTH trial, have argued this may have made the placebo group look artificially worse, inflating the apparent benefit of icosapent ethyl. Other researchers, including REDUCE-IT's own investigators, argue the biomarker changes were too small to explain the trial's large risk reduction. Both trials showed similarly large increases in blood EPA levels, and STRENGTH still found no cardiovascular benefit, which is central to the disagreement.

Q: Does fish oil increase the risk of atrial fibrillation?

It depends heavily on dose and how omega-3 is measured. Large meta-analyses of pharmaceutical-strength omega-3 trials (typically 1.8 to 4 grams per day) found a dose-dependent increase in atrial fibrillation risk, reaching about 48-50% relative risk increase at the highest doses in people already at high cardiovascular risk. In contrast, studies measuring omega-3 blood levels from diet or moderate supplementation have generally found higher levels associated with lower atrial fibrillation risk. The apparent contradiction is resolved by dose: moderate intake appears neutral to protective, while high pharmaceutical doses in high-risk patients carry a real, measurable increased risk.

Q: Is EPA or DHA better for depression?

The evidence consistently favors EPA. Multiple meta-analyses have found that omega-3 formulations containing at least 60% EPA produce a measurable antidepressant effect, while DHA-only or DHA-dominant formulations show no significant benefit for depression in the same analyses. This is a specific, well-replicated finding, not a general claim that all omega-3 helps mood equally.

Q: Does omega-3 help prevent macular degeneration?

No, despite strong biological plausibility. DHA is a major structural component of retinal photoreceptor membranes, and observational studies suggested a protective association. But the large AREDS2 randomized trial, which added DHA and EPA to the standard AREDS supplement formula in people at high risk of advanced macular degeneration, found no reduction in disease progression compared with placebo.

Q: Is triglyceride-form fish oil really better absorbed than ethyl ester?

Yes, this is well-documented. A controlled comparison study found re-esterified triglyceride (rTG) fish oil had about 124% the bioavailability of natural fish oil triglycerides, free fatty acid form had about 91%, and ethyl ester form had only about 73%. Ethyl ester absorption is also more dependent on taking it with a fat-containing meal than triglyceride forms are.

Q: Is algae oil as good as fish oil for omega-3?

For DHA specifically, yes — a small comparative study found DHA from algal oil was absorbed about as well as DHA from cooked salmon. Algae oil is naturally in triglyceride form. The main practical difference is that most algal oil supplements are DHA-dominant with little or no EPA, so people specifically wanting EPA (for its distinct depression or triglyceride-lowering evidence) may need an EPA-supplemented algae product or a different source.

Strong Triglyceride & Structural Evidence · Genuinely Contested Trial Evidence Elsewhere

Biological Overview

Omega-3 fatty acids are a family of polyunsaturated fats built into cell membranes throughout the body, where they influence membrane fluidity, get converted into anti-inflammatory signaling molecules, and serve as structural components of neural and retinal tissue. The three nutritionally relevant omega-3s are alpha-linolenic acid (ALA, found in plants), and eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA, found mainly in marine sources). Only ALA is considered a true essential fatty acid the body cannot make at all; EPA and DHA can technically be synthesized from ALA, but the conversion is inefficient enough that food or supplement sources of EPA/DHA directly are considered the practical way to meet the body's needs. Omega-3 also has an unusually large gap between its biological plausibility and its trial evidence in several specific areas — a gap this page treats as worth explaining rather than smoothing over.

Essential FormALA (plant-derived)

Bioactive Marine FormsEPA & DHA

ALA→EPA/DHA ConversionInefficient (~6% / <4%)

Strongest EvidenceTriglyceride Reduction · Fetal Brain Development

Supplement Classification

Overview & Classification

Class: Polyunsaturated fatty acids (PUFAs)
Essential Form: ALA (18:3 n-3)
Key Bioactive Forms: EPA (20:5 n-3), DHA (22:6 n-3)
Adult AI (as ALA): 1.6 g (men), 1.1 g (women)
Tolerable Upper Limit: Not established
General Safety Guidance: ≤3 g/day EPA+DHA combined
Common Supplement Forms: Ethyl ester, triglyceride, rTG, phospholipid, algae
FDA-Approved Drug Use: Severe hypertriglyceridemia (prescription-strength)

What Omega-3 Actually Does

Omega-3 Benefits

Every benefit below is backed by an RCT, meta-analysis, or FDA-recognized indication. Two of the most-marketed omega-3 claims are genuinely more contested than presented here, and get their own full treatment in Clinical Indications, below.

💉

Triglyceride Reduction Strong

FDA-approved prescription indication

High-dose EPA and/or DHA reliably lowers triglycerides by reducing hepatic VLDL production, an effect strong and consistent enough that prescription-strength omega-3 formulations are FDA-approved specifically for severe hypertriglyceridemia. ^[1]

❤️

Cardiovascular Event Reduction Contested

One major trial positive, one major trial null

The REDUCE-IT trial found a large reduction in cardiovascular events with high-dose icosapent ethyl (pure EPA), while the STRENGTH trial, testing a combined EPA/DHA formulation at a similar dose, found no benefit. ^[2],[3]
Why these two major trials disagree is genuinely unresolved and gets its own full breakdown in Clinical Indications, below — this is not a settled "omega-3 prevents heart attacks" claim.

🧠

Fetal & Infant Brain Development Strong

DHA specifically

DHA is a major structural component of neural and retinal cell membranes and accumulates rapidly in the fetal brain during the third trimester, making adequate maternal DHA intake important for normal neurodevelopment. ^[4]

💫

Mood Support Form-Specific

EPA-dominant formulations only

Multiple meta-analyses consistently find omega-3 formulations with at least 60% EPA produce a measurable antidepressant effect, while DHA-only or DHA-dominant formulations show no significant benefit for depression in the same analyses. ^[5],[6]
This is a specific, well-replicated, form-dependent finding — not a general "omega-3 helps mood" claim, covered further in Clinical Indications.

The Deeper Evidence

Clinical Indications by Evidence Tier

Four genuinely contested or counterintuitive findings get the depth a single benefit tile can't hold.

A Trial Disagreement Its Own Investigators Haven't Resolved

REDUCE-IT vs. STRENGTH: was it the fish oil, or the placebo?

REDUCE-IT randomized 8,179 statin-treated patients with elevated triglycerides to 4g/day of icosapent ethyl (a purified EPA drug) or a mineral oil placebo, and found a large, statistically robust 25% relative reduction in major cardiovascular events. ^[2] STRENGTH tested a combined EPA/DHA carboxylic acid formulation at a similar dose against a corn oil placebo in a similar high-risk population, and found no cardiovascular benefit at all. ^[3] Blood EPA levels rose dramatically in both trials — in fact, STRENGTH participants with the largest EPA increases (higher than REDUCE-IT's average increase) still showed no benefit.

A subsequent biomarker analysis of REDUCE-IT found that patients in the mineral oil placebo group had significant increases over the trial in LDL cholesterol (+10.2%), oxidized LDL, C-reactive protein, interleukin-6, interleukin-1-beta, lipoprotein(a), and homocysteine — every marker moved in the direction associated with higher cardiovascular risk. ^[7] No comparable biomarker drift occurred in the corn-oil placebo arm of STRENGTH, or in the placebo arms of several other major cardiovascular trials unrelated to omega-3. ^[8] This has led some researchers, including STRENGTH's senior investigator, to argue that REDUCE-IT's placebo group may have looked artificially worse over time, inflating the apparent benefit of the active drug.

The honest summary: this is a live, unresolved dispute among cardiologists, not a settled matter either way. A review of mineral oil's safety literature found no consistent pattern of adverse effects across dozens of prior studies using it as a placebo, and REDUCE-IT's own investigators argue the biomarker shifts were too small to explain a 25% relative risk reduction on their own. ^[9] Other EPA-specific trials (JELIS, EVAPORATE) have also shown positive results, which complicates a simple "it was all the placebo" explanation. ^[10] What can be said plainly: this remains one of the most-debated placebo-design questions in modern cardiology, and both trials' investigators still disagree about what it means.

⚠ The atrial fibrillation paradox: high-dose treatment and high blood levels point opposite directions

A meta-analysis of 34 RCTs covering over 114,000 people found that high-dose pharmaceutical EPA/DHA (above 1,500 mg/day) significantly increased atrial fibrillation risk specifically in patients already at high cardiovascular risk — a pooled odds ratio of 1.48, meaning about a 48% relative increase, with an absolute risk difference of roughly 0.8%. No significant increase was found in any other combination of dose and risk level. ^[11]

Separately, studies measuring omega-3 status directly in the blood, rather than assigning a supplement dose, have generally found the opposite pattern: higher circulating omega-3 levels are associated with lower atrial fibrillation risk, and fish oil supplement use in large cohort data shows no consistent association with increased risk either. ^[12] One proposed mechanism for the high-dose signal involves vagal tone: omega-3s increase vagal tone in a dose-dependent way, and while low-level vagal stimulation is anti-arrhythmic, high-level stimulation is a known way to induce atrial fibrillation in animal models. ^[13] The practical takeaway: moderate dietary and supplemental intake (roughly 250-1,500mg/day) appears neutral to protective; the real, measurable risk applies specifically to pharmaceutical-strength doses in people already at elevated cardiovascular risk.

💫

EPA vs. DHA for Depression

A Consistent, Replicated Split

Finding: across multiple independent meta-analyses, formulations with EPA ≥60% of total EPA+DHA showed significant antidepressant effects, while DHA-pure or DHA-major formulations consistently showed none. ^[5],[6]
Proposed mechanism: EPA appears more anti-inflammatory and may increase BDNF and monoamine neurotransmission more than DHA, though the biology isn't fully settled.

👁️

AREDS2 — A Biologically Obvious Benefit That Didn't Show Up

Large RCT, Null Result

Why expectations were high: DHA is a major structural component of photoreceptor membranes, and prior observational data linked higher blood EPA/DHA to lower macular degeneration risk. ^[14]
What the trial found: adding 650mg EPA + 350mg DHA daily to the standard AREDS supplement formula produced no reduction in progression to advanced macular degeneration in over 4,200 high-risk participants. ^[15]

Biochemistry

Mechanisms of Action

Omega-3's mechanisms span membrane structure, lipid metabolism, and a specialized anti-inflammatory signaling system most people have never heard named.

🧬

Membrane Incorporation & Fluidity

EPA and DHA are incorporated directly into cell membrane phospholipids throughout the body, where their multiple double bonds increase membrane fluidity and affect the function of embedded proteins, ion channels, and receptors. ^[16]

🛡️

Resolvins & Specialized Pro-Resolving Mediators

EPA and DHA are converted into resolvins, protectins, and maresins — a family of signaling molecules that actively resolve inflammation, rather than simply blocking it, distinct from the eicosanoid-blocking mechanism of anti-inflammatory drugs. ^[17]

💉

VLDL Synthesis & Triglyceride Lowering

High-dose EPA/DHA reduces hepatic synthesis and secretion of VLDL particles, the primary carrier of triglycerides in the blood, which is the direct mechanistic basis for omega-3's FDA-approved triglyceride-lowering indication. ^[1]

🧠

Retinal & Neural Structural Role

DHA makes up a substantial share of the fatty acids in photoreceptor outer segment membranes and neural synaptic membranes, where it's required for normal membrane fluidity, photoreceptor function, and is continuously resupplied as these membranes are shed and renewed. ^[18]

⚖️

Vagal Tone Modulation

Omega-3s increase cardiac vagal tone in a dose-dependent way, beginning at relatively low doses (~500mg/day). Low-level vagal stimulation is generally anti-arrhythmic, but very high-level stimulation is a recognized way to induce atrial fibrillation experimentally — a proposed explanation for the dose-dependent AFib signal discussed in Clinical Indications above. ^[13]

🔬

The ALA Conversion Bottleneck

Converting plant-derived ALA into EPA and DHA requires the same desaturase and elongase enzymes used to process omega-6 fatty acids, which are typically consumed in much greater quantity, creating competition that limits conversion. Isotope-tracer studies estimate only about 6% of ALA converts to EPA and under 4% converts to DHA. ^[19]

An AI for ALA Only — EPA/DHA Have No Official Target

Dosage & Intake Levels

Formal intake recommendations exist only for ALA. EPA and DHA have widely-used expert guidance figures, but no official RDA or AI of their own.

Life Stage / Context	Recommendation	Tolerable Upper Limit	Notes
Adult men (ALA)	1.6 g/day	Not established	Adequate Intake, not RDA — based on healthy population intake data ^[20]
Adult women (ALA)	1.1 g/day	Not established	1.4g in pregnancy, 1.3g in lactation
General EPA+DHA guidance (no official AI)	250–500 mg/day	≤3 g/day (FDA general guidance)	Widely cited expert consensus figure, not a formal Dietary Reference Intake ^[21]
Prescription-strength (severe hypertriglyceridemia)	4 g/day EPA (or EPA+DHA)	Medically supervised	FDA-approved drug dose; not a self-directed supplement target ^[1]

Why is there no official AI or RDA for EPA and DHA?

Because ALA is the only omega-3 formally classified as essential, the National Academies has not set a separate Dietary Reference Intake for EPA or DHA specifically — the widely-cited 250-500mg/day figure comes from expert consensus groups, not the same regulatory process as the ALA AI. ^[21]

Is the 3g/day ceiling a hard safety limit?

No formal Tolerable Upper Intake Level has been established; the 3g/day figure is general FDA guidance for combined EPA+DHA intake from food and supplements, with higher prescription doses used specifically under medical supervision for diagnosed hypertriglyceridemia. ^[1]

Total Fish Oil vs. Actual Active Omega-3

Reading an Omega-3 Supplement Label

This is the single most common source of confusion in the entire supplement category: the large number on the front of the bottle usually isn't the number that matters.

"1000mg fish oil" is not 1000mg of omega-3

Fish oil is a mix of fatty acids; only a fraction is the actual EPA and DHA responsible for its effects.

1000mg "Fish Oil" (front of label) Standard, unconcentrated fish oil often contains only around 300mg of combined EPA+DHA — the rest is other fatty acids, primarily saturated and monounsaturated fat.

→

~300mg Actual EPA + DHA This is the figure on the Supplement Facts panel that actually corresponds to the clinical evidence for omega-3. Concentrated products state a higher EPA+DHA percentage of total oil.

Quick reference: what to actually check on the label

Look for the Supplement Facts panel breakdown, which should list EPA and DHA separately in milligrams — that combined figure, not the "fish oil" or "omega-3" total on the front, is what to compare against the ~250-500mg/day general guidance or any specific target. Also check the form (ethyl ester, triglyceride, rTG, phospholipid) covered fully in Form Comparison, below, since it affects how much of that labeled amount actually gets absorbed.

⚠ Oxidation (TOTOX) is a real, testable quality issue

Fish oil's polyunsaturated fats are chemically prone to oxidation, which degrades potency and produces compounds linked to unpleasant taste and, in animal studies, potential harm at high levels. Third-party testing programs check a Total Oxidation (TOTOX) value against voluntary industry limits; products that disclose TOTOX testing results are a meaningfully different quality signal than products that don't mention oxidation testing at all.

Real, Measured Bioavailability Differences

Form Comparison

Omega-3 supplement chemistry genuinely affects how much reaches your bloodstream — with a roughly 70% gap between the best- and worst-absorbed common forms.

Form	Chemistry	Relative Bioavailability	Meal-Fat Dependence	Notes
Re-Esterified Triglyceride (rTG)	Ethyl ester converted back to a triglyceride-like structure	124%	Lower	Highest measured bioavailability; typically 55-60% true triglyceride plus di/monoglycerides ^[22]
Natural Triglyceride (Fish Oil, Algae Oil)	The form found naturally in fish and algae	100% (reference)	Lower	Reference standard other forms are compared against
Free Fatty Acid (FFA)	EPA/DHA not bound to glycerol or ethanol	91%	Moderate	Comparable to natural triglyceride absorption ^[22]
Ethyl Ester (EE)	EPA/DHA chemically bound to ethanol	73%	Higher — needs dietary fat	Lowest measured bioavailability; common in high-concentration, lower-cost products ^[22]
Phospholipid (Krill Oil)	EPA/DHA bound to a phosphatidylcholine backbone	Comparable to or modestly higher than triglyceride at equivalent doses	Lower	Naturally low EPA+DHA concentration per gram of oil; often contains astaxanthin

Algae oil: a real DHA alternative, with one practical caveat

A comparative study found DHA from algal oil absorbed about as well as DHA from cooked salmon, and most algal oil is naturally in the well-absorbed triglyceride form. ^[23] The practical caveat: most algal oil supplements are DHA-dominant with little or no EPA, so anyone specifically seeking EPA's distinct depression or triglyceride-lowering evidence needs an EPA-supplemented algae product or a different source — not all "vegan omega-3" products deliver the same EPA:DHA ratio as fish oil.

Pharmacology

Nutrient–Nutrient Interactions

Omega-3's most practically relevant nutrient interaction is protective, not competitive: the antioxidant vitamin that keeps it from oxidizing before your body can use it.

Nutrient	Interaction Type	Mechanism	Clinical Relevance	Evidence Quality
Vitamin E	Protective	Vitamin E's antioxidant activity helps protect the polyunsaturated double bonds in EPA/DHA from oxidation, both in the supplement itself and after absorption into cell membranes. ^[24]	Moderate: part of why many fish oil supplements include added vitamin E as a preservative, distinct from vitamin E's own nutrient functions.	Established biochemistry
Omega-6 Fatty Acids	Competitive	ALA-to-EPA/DHA conversion uses the same desaturase and elongase enzymes as omega-6 metabolism; typical Western diets contain far more omega-6 than omega-3, creating competition that further limits ALA conversion. ^[19]	Moderate: relevant mainly to people relying on ALA alone rather than direct EPA/DHA sources.	Established enzyme biochemistry
Vitamin D (Cod Liver Oil Specifically)	Co-Occurring, Not Interacting	Cod liver oil naturally contains substantial vitamin A and vitamin D alongside omega-3s, unlike standard fish body oil, which contains negligible amounts of either. ^[25]	Moderate: relevant to the safety profile of cod liver oil specifically, covered further in Safety, below — this isn't a biochemical interaction, but a labeling/product distinction worth knowing.	Established nutrient composition data

Targeted Populations

Who Needs Omega-3 Most

The clearest need cases track either poor conversion capacity or a specific, well-evidenced clinical indication.

Diet-Linked

Vegans & Vegetarians

Reliant entirely on ALA, which converts to EPA and especially DHA very inefficiently, making algae-based direct EPA/DHA sources the most reliable option for this population. ^[19]

Life-Stage-Linked

Pregnant & Breastfeeding Women

The population with the clearest DHA-specific structural need, given rapid fetal brain DHA accumulation in the third trimester. ^[4]

Condition-Linked

People With Severe Hypertriglyceridemia

The population with an actual FDA-approved, prescription-strength indication for high-dose omega-3 therapy under medical supervision. ^[1]

Diet-Linked

People Who Rarely Eat Fatty Fish

The most straightforward, food-first population for supplementation, given how concentrated EPA/DHA are in oily fish relative to other dietary sources.

Condition-Linked

People With EPA-Responsive Depression

Specifically those using or considering an EPA-dominant (≥60% EPA) formulation as an adjunct to standard depression treatment, per the evidence in Clinical Indications above. ^[5]

Caution-Linked

People Already at High Cardiovascular Risk

The specific population in whom high-dose pharmaceutical omega-3 carries a measurable atrial fibrillation risk increase, worth discussing with a cardiologist rather than self-directing. ^[11]

Pharmacology

Drug Interactions

Omega-3's most relevant drug interaction is a real but generally modest additive effect on bleeding risk.

Drug / Drug Class	Direction	Recommendation
Anticoagulants (warfarin) & antiplatelets (aspirin, clopidogrel)	Additive bleeding risk	High-dose omega-3 has mild antiplatelet effects of its own; combined use is generally considered safe at moderate doses but warrants medical awareness, particularly before surgery. ^[26]
Blood pressure medications	Additive blood-pressure-lowering effect	High-dose omega-3 modestly lowers blood pressure; generally not a concern at typical doses but worth monitoring at prescription-strength doses.

Safety & Contraindications

Safety & AFib Risk

🚫

When to Use Caution

High cardiovascular risk plus pharmaceutical-strength dosing: the specific population and dose range with a documented atrial fibrillation risk increase, per Clinical Indications above. ^[11]
Upcoming surgery or bleeding disorders: discuss high-dose omega-3 use with a physician given the additive antiplatelet effect.
Cod liver oil specifically: its natural vitamin A and D content means chronic high intake carries a real hypervitaminosis A risk that standard fish body oil does not. ^[25]
On anticoagulant or antiplatelet medication: coordinate omega-3 use with the prescribing physician.

⚠️

Common, Generally Mild Side Effects

Fishy aftertaste, bad breath, heartburn: among the most commonly reported side effects at standard doses, often improved by taking supplements with food or choosing enteric-coated products. ^[27]
Nausea and stomach discomfort: generally mild and dose-related.
Oxidized (rancid) product: a real quality issue distinct from the nutrient's own safety profile, covered in Label Guide above.

Medical disclaimer: This reference is for educational purposes only and does not constitute medical advice, diagnosis, or treatment guidance. High-dose omega-3 carries a genuine atrial fibrillation risk in people with elevated cardiovascular risk, and interacts with anticoagulant and antiplatelet medications. Anyone with a heart condition, a bleeding disorder, or taking blood thinners should consult a qualified healthcare provider before starting high-dose omega-3 supplementation.

Frequently Asked Questions

Omega-3 FAQ

Answers to the specific trial, dosing, and safety questions most often raised about omega-3.

Did the REDUCE-IT trial's benefit come from a bad placebo, not the fish oil?

This is a genuine, unresolved controversy. Mineral oil placebo recipients showed rising LDL, inflammatory markers, and other risk markers over the trial. ^[7] Critics argue this inflated the apparent benefit; REDUCE-IT's investigators argue the changes were too small to explain the result, and other EPA trials have also shown benefit. ^[9],[10]

Does fish oil increase the risk of atrial fibrillation?

Only at pharmaceutical doses (>1,500mg/day) in people already at high cardiovascular risk, where a meta-analysis found about a 48% relative risk increase. ^[11] Higher blood omega-3 levels from diet or moderate supplementation are generally associated with lower, not higher, AFib risk. ^[12]

Is EPA or DHA better for depression?

EPA. Formulations with at least 60% EPA show a consistent antidepressant effect across meta-analyses, while DHA-dominant formulations show none in the same analyses. ^[5],[6]

Does omega-3 help prevent macular degeneration?

No — despite DHA's structural importance in retinal photoreceptors, the large AREDS2 trial found no reduction in progression to advanced macular degeneration when EPA/DHA was added to the standard supplement formula. ^[15]

Is triglyceride-form fish oil really better absorbed than ethyl ester?

Yes — a controlled study found re-esterified triglyceride form had about 124% the bioavailability of natural fish oil, versus 91% for free fatty acid form and only 73% for ethyl ester. ^[22]

Is algae oil as good as fish oil for omega-3?

For DHA, yes — a comparative study found algal DHA absorbed about as well as DHA from cooked salmon. ^[23] The catch: most algal oil is DHA-dominant with little EPA, so it isn't a complete substitute for people specifically seeking EPA's distinct benefits.

References

Bibliography

Numbered references for every claim made on this page, drawn from peer-reviewed literature and NIH fact sheets.

↑ 1. Office of Dietary Supplements, NIH. Omega-3 Fatty Acids — Fact Sheet for Health Professionals (triglyceride-lowering, FDA-approved indication). NIH ODS →

↑ 2. Bhatt DL, Steg PG, Miller M, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia (REDUCE-IT). N Engl J Med. 2019;380:11–22. PubMed →

↑ 3. Nicholls SJ, Lincoff AM, Garcia M, et al. Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events (STRENGTH). JAMA. 2020;324(22):2268–2280. PubMed →

↑ 4. Office of Dietary Supplements, NIH. Dietary Supplements for Pregnancy — Health Professional Fact Sheet (DHA, fetal neurodevelopment). NIH ODS →

↑ 5. Martins JG. EPA but not DHA appears to be responsible for the efficacy of omega-3 LC-PUFA supplementation in depression. J Am Coll Nutr. 2009. PubMed →

↑ 6. Liao Y, Xie B, Zhang H, et al. Efficacy of omega-3 PUFAs in depression: A meta-analysis. Transl Psychiatry. 2019;9:190. PubMed →

↑ 7. Olshansky B, Chung MK, Budoff MJ, et al. Mineral oil: safety and use as placebo in REDUCE-IT and other clinical studies. Eur Heart J Suppl. 2020;22(Suppl J):J34–J48. PubMed →

↑ 8. Comparative biomarker changes in mineral oil versus corn oil placebo arms across cardiovascular trials. Cited in REDUCE-IT/STRENGTH comparative commentary literature. Cited in PubMed PMID: 33061859 →

↑ 9. Bhatt DL, Miller M, Brinton EA, et al. Response to the mineral oil placebo controversy in REDUCE-IT. Investigator commentary and rebuttal literature. Cited in PubMed PMID: 33061859 →

↑ 10. Yokoyama M, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS). Lancet. 2007;369(9567):1090–1098. PubMed →

↑ 11. Effects of Omega-3 Fatty Acid Treatment on Risk for Atrial Fibrillation: An Updated Meta-Analysis of 34 Trials including 114,326 Individuals. PMC12723971 →

↑ 12. Associations Between Plasma Omega-3 and Fish Oil Use With Risk of Atrial Fibrillation in the UK Biobank. J Am Heart Assoc. JAHA →

↑ 13. Omega-3 and Risk of Atrial Fibrillation: Vagally-Mediated Double-Edged Sword. PMC12122841 →

↑ 14. Age-related Macular Degeneration (AMD) in the Vitamin D and Omega-3 Trial (VITAL). Background on DHA's structural retinal role. ClinicalTrials.gov →

↑ 15. Age-Related Eye Disease Study 2 Research Group. Lutein + Zeaxanthin and Omega-3 Fatty Acids for Age-Related Macular Degeneration (AREDS2). JAMA. 2013;309(19):2005–2015. Summary →

↑ 16. Office of Dietary Supplements, NIH. Omega-3 Fatty Acids — Fact Sheet for Health Professionals (membrane incorporation). NIH ODS →

↑ 17. Resolvins, protectins, and maresins: specialized pro-resolving mediators. Standard lipid biochemistry and inflammation resolution literature. Cited in NIH ODS →

↑ 18. DHA in photoreceptor outer segment membranes and retinal function. Cited in VITAL trial AMD protocol and retinal physiology literature. ClinicalTrials.gov →

↑ 19. Burdge GC, Calder PC. Can adults adequately convert alpha-linolenic acid to eicosapentaenoic acid and docosahexaenoic acid? Reprod Nutr Dev. 2005. PubMed →

↑ 20. Office of Dietary Supplements, NIH. Omega-3 Fatty Acids — Fact Sheet for Health Professionals (ALA Adequate Intake values). NIH ODS →

↑ 21. Office of Dietary Supplements, NIH. Omega-3 Fatty Acids — Consumer Fact Sheet (EPA/DHA general guidance, no formal DRI). NIH ODS →

↑ 22. Dyerberg J, Madsen P, Møller JM, Aardestrup I, Schmidt EB. Bioavailability of marine n-3 fatty acid formulations. Prostaglandins Leukot Essent Fatty Acids. 2010. PubMed →

↑ 23. Office of Dietary Supplements, NIH. Omega-3 Fatty Acids — Fact Sheet for Health Professionals (algal oil bioavailability vs. cooked salmon). NIH ODS →

↑ 24. Vitamin E as an antioxidant preservative in polyunsaturated fatty acid formulations. Standard lipid stability and formulation chemistry literature. Cited in NIH ODS →

↑ 25. Cod liver oil vitamin A and D content versus standard fish body oil. Standard nutrient composition and toxicology literature. Cited in NIH ODS →

↑ 26. Office of Dietary Supplements, NIH. Omega-3 Fatty Acids — Consumer Fact Sheet (anticoagulant/antiplatelet interaction). NIH ODS →

↑ 27. Office of Dietary Supplements, NIH. Omega-3 Fatty Acids — Consumer Fact Sheet (common side effects). NIH ODS →

Additional Reference Literature

Office of Dietary Supplements, NIH. Omega-3 Fatty Acids — Consumer Fact Sheet. Plain-language overview of intake, food sources, and safety. NIH ODS →

Comparative membrane incorporation of omega-3 fish oil triglyceride preparations differing by degree of re-esterification. PLOS One. 2023. Further detail on rTG variability and bioavailability. PLOS One →

Harris WS, von Schacky C. The Omega-3 Index: a new risk factor for death from coronary heart disease? Prev Med. Foundational paper on the Omega-3 Index biomarker concept.

The influence of dietary and supplemental omega-3 fatty acids on the omega-3 index: A scoping review. Background on blood-level-based omega-3 assessment. PMC9892774 →